Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFTISARC-NEO neoadjuvant pembrolizumab + eftilagimod alpha + radiotherapy in resectable soft tissue sarcomas
2024-515971-37-00Phase 2Authorised
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and eftilagimod alpha in soft tissue sarcoma (STS), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: Pathological response. Planned start Oct 2024; status: authorised.
02
Drugs
pembrolizumabeftilagimod alpha
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2024-515971-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515971-37-00.